State Street Corp Gain Therapeutics, Inc. Transaction History
State Street Corp
- $2.21 Trillion
- Q1 2024
A detailed history of State Street Corp transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 30,837 shares of GANX stock, worth $39,471. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,837Holding current value
$39,471% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
33Shares Held
2.58MCall Options Held
22.2KPut Options Held
16K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$753,1640.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$724,6460.1% of portfolio
-
Raymond James & Associates St Petersburg, FL260KShares$332,8240.0% of portfolio
-
Royal Bank Of Canada Toronto, A6249KShares$318,0800.0% of portfolio
-
Geode Capital Management, LLC Boston, MA177KShares$226,6760.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $15.2M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...